

PATIENT INFORMATION

PERSONAL INFORMATION		SAMPLE INFORMATION		TEST INFORMATION	
Full Name:	Sample Patient	Sample Type:	Blood	Ordering Physician:	Dr. GS
NRIC/Passport/ID:	Xxxx Xxxxx Xxxxxx	Date Collected:	01/01/2025	MCR/MMC no.:	Xxxx Xxxxx Xxxxxx
Gender:	Female	Date Received by Lab:	02/01/2025	Sample Collection Place:	Sample Hospital
Date of Birth:	19/01/1987			Date Reported:	20/01/2025


CLINICAL INFORMATION

Remark:	An in-depth analysis and commentary on a clinical topic, supported by the latest evidence and insights. Clinical comments can also include personal experiences.
---------	--

RESULT

 LABCODE ID: SAAAAAR29 | ECD ID: ECDXXX01 | PERFORMED TEST:  SPOT-MAS

RISK ASSESSMENT



Scope of Investigation
ctDNA signal

Z-score
2.00

Result
Intermediate Signal

- Negative Score: <2
- Intermediate Score: 2-3
- Positive Score: >3

ctDNA (circulating tumor DNA) is DNA released from cancerous cells and tumors, circulating freely in the bloodstream.

What Your Result Means:

There is **intermediate signal** in the subthreshold range to a positive level.
It is recommended to repeat this test within 06 months

This result is only valid on the received sample


NOTE:

- The positive predictive value of the test is 39.5% for cancerous lesions and 58.1% when combined with the assessment of precancerous lesions in the digestive tract^(1,2), which means that for **every 100 positive cases, about 58 cases will have cancerous or precancerous lesions.**
- The negative predictive value of the test is 99.9%⁽¹⁾, which means that for **every 1000 ASYMPTOMATIC cases with negative results, about 999 cases actually do not have cancer.**
- Recommend using this test as a supporting screening test, **NOT** as a substitute for recommended routine cancer screening tests. You should continue to have regular health check-ups and cancer screenings as instructed by your doctor.
- If you have any symptoms that suspect you have cancer, you should immediately notify your doctor or visit a medical facility. Delaying medical examination when there are suspicious symptoms will lead to the risk of diagnosing cancer at a late stage.

(1) Nguyen, L.H.D. et al. Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. *BMC Med* 23, 90 (2025). doi:10.1186/s12916-025-03929-y.

(2) Carbonell, Chantelle, et al. *Cancer Control* 31 (2024): doi:10732748241307360.

Notice: The performance of the test is based on data from the K-DETEK clinical validation study (ClinicalTrials.gov ID: NCT05227261).


TUMOR-OF-ORIGIN PREDICTION

Ovarian and endometrial cancer screening scope applies to females only.

This report is electronically signed by

Laboratory Director

Christopher Wong, PhD

Gene Solutions Singapore

 5 Tai Seng Avenue #02-54, Singapore 536671
MOH license: L/2411577/CLB/001/242